CareDx, Inc operates as a transplant diagnostics company,which discovers, develops, and commercializes diagnostic solutions. Its product includes AlloMap, AlloSure, and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone415-287-2300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$76.57 million
Profitability
Miscellaneous
Employees227
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
CareDx (NASDAQ:CDNA) Frequently Asked Questions
What is CareDx's stock symbol?
CareDx trades on the NASDAQ under the ticker symbol "CDNA."
How were CareDx's earnings last quarter?
CareDx Inc (NASDAQ:CDNA) released its earnings results on Thursday, August, 1st. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by $0.07. The firm had revenue of $31.45 million for the quarter, compared to analysts' expectations of $27.96 million. CareDx had a negative net margin of 38.29% and a negative return on equity of 47.53%. View CareDx's Earnings History.
When is CareDx's next earnings date?
What guidance has CareDx issued on next quarter's earnings?
CareDx issued an update on its FY 2019 earnings guidance on Thursday, August, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $123-125 million, compared to the consensus revenue estimate of $115.17 million.
What price target have analysts set for CDNA?
5 equities research analysts have issued 1-year target prices for CareDx's stock. Their forecasts range from $35.00 to $63.00. On average, they anticipate CareDx's stock price to reach $47.40 in the next year. This suggests a possible upside of 112.6% from the stock's current price. View Analyst Price Targets for CareDx.
What is the consensus analysts' recommendation for CareDx?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CareDx.
What are Wall Street analysts saying about CareDx stock?
Here are some recent quotes from research analysts about CareDx stock:
- 1. According to Zacks Investment Research, "CareDx, Inc. is a commercial stage company. It develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients. The Company provides AlloMap, a noninvasive blood test used to aid in the identification of heart transplant recipients. It is also pursuing other areas of transplant surveillance, such as the use of cell-free DNA (cfDNA) as a biomarker for rejection. CareDx, Inc. is based in Brisbane, California. " (8/7/2019)
- 2. HC Wainwright analysts commented, "Our 12-month price target is based on an estimated market value of the firm at $1.83B, which includes a discounted cash flow analysis based asset value for pre- and post-transplant tests, using a 10% discount rate and 2% terminal growth rate, and assuming 43M shares outstanding at the end of 1Q20. Investment risks include: (1) failure of to achieve commercial success due to market size, penetration rate, and/or competition; and (2) potential dilution risk. CareDx, Inc." (5/9/2019)
Has CareDx been receiving favorable news coverage?
News coverage about CDNA stock has trended somewhat positive recently, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. CareDx earned a news impact score of 0.9 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for CareDx.
Who are some of CareDx's key competitors?
Some companies that are related to CareDx include Genomic Health (GHDX), Natera (NTRA), InVitae (NVTA), Veracyte (VCYT), RadNet (RDNT), Personalis (PSNL), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Celcuity (CELC), Enzo Biochem (ENZ), Psychemedics (PMD), Miragen Therapeutics (MGEN), PotNetwork (POTN), Biocept (BIOC) and Avant Diagnostics (AVDX).
What other stocks do shareholders of CareDx own?
Who are CareDx's key executives?
CareDx's management team includes the folowing people:
- Peter K. Maag, Chief Executive Officer & Director
- Reginald Seeto, President & Chief Business Officer
- Paul Ciccolella, Senior Vice President-Global Operations
- Michael Bell, Chief Financial & Principal Accounting Officer
- James P. Yee, Chief Medical Officer & Executive Vice President
Who are CareDx's major shareholders?
CareDx's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.63%), Vanguard Group Inc. (5.01%), Waddell & Reed Financial Inc. (4.36%), Gagnon Securities LLC (2.39%), Wells Fargo & Company MN (1.73%) and Invesco Ltd. (1.46%). Company insiders that own CareDx stock include James P Yee, Michael Brian Bell, Michael Goldberg, Mitchell J Nelles, Neil Gagnon, Peter Maag, Sasha King and William A Hagstrom. View Institutional Ownership Trends for CareDx.
Which major investors are selling CareDx stock?
CDNA stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Vanguard Group Inc., Gagnon Securities LLC, Russell Investments Group Ltd., Gagnon Advisors LLC, Bank of America Corp DE, Peregrine Capital Management LLC and AWM Investment Company Inc.. Company insiders that have sold CareDx company stock in the last year include James P Yee, Michael Brian Bell, Michael Goldberg, Neil Gagnon, Peter Maag, Sasha King and William A Hagstrom. View Insider Buying and Selling for CareDx.
Which major investors are buying CareDx stock?
CDNA stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Waddell & Reed Financial Inc., D. E. Shaw & Co. Inc., BlackRock Inc., Intrinsic Edge Capital Management LLC, William Blair Investment Management LLC, Invesco Ltd. and JPMorgan Chase & Co.. View Insider Buying and Selling for CareDx.
How do I buy shares of CareDx?
Shares of CDNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is CareDx's stock price today?
One share of CDNA stock can currently be purchased for approximately $22.30.
How big of a company is CareDx?
CareDx has a market capitalization of $945.07 million and generates $76.57 million in revenue each year. The company earns $-46,760,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. CareDx employs 227 workers across the globe.View Additional Information About CareDx.
What is CareDx's official website?
How can I contact CareDx?
CareDx's mailing address is 3260 BAYSHORE BOULEVARD, BRISBANE CA, 94005. The company can be reached via phone at 415-287-2300 or via email at [email protected]
MarketBeat Community Rating for CareDx (NASDAQ CDNA)
MarketBeat's community ratings are surveys of what our community members think about CareDx and other stocks. Vote "Outperform" if you believe CDNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
